Oculis Holding AG issued 2.5 million treasury shares, maintaining 7.2% of total registered shares, under an ATM program.
Quiver AI Summary
Oculis Holding AG, a biopharmaceutical company based in Zug, Switzerland, has issued 2,500,000 registered ordinary shares with a nominal value of CHF 0.01, recorded as treasury shares, under its existing capital band. This issuance brings the total number of treasury shares to 7.2% of the company's registered shares, which total approximately 48.9 million. The shares were related to a sales agreement with Leerink Partners LLC, allowing for an at-the-market offering program with a potential aggregate value of up to $100 million, though the newly issued shares have not yet been sold under this program and will be reserved as treasury shares. Additional details about the offering can be found in previous press releases and SEC filings by the company.
Potential Positives
- Oculis Holding AG successfully issued 2,500,000 registered ordinary shares, increasing its treasury shares to 7.2% of the Company’s registered shares, which can provide financial flexibility.
- The Company has a significant ATM offering program capacity with the potential to raise up to $100 million, enhancing its fundraising capabilities for future initiatives.
Potential Negatives
- The issuance of treasury shares indicates potential dilution of existing shareholders’ equity, which can negatively impact shareholder value and confidence.
- The fact that these shares are being held in reserve suggests that the company may be preparing for future sales, raising concerns about its cash flow and reliance on further capital raises.
- The announcement of an ATM offering program may signal to investors that the company is in need of liquidity, which could be perceived negatively in terms of financial health.
FAQ
What is the recent share issuance by Oculis Holding AG?
Oculis issued 2,500,000 registered ordinary shares, increasing the number of treasury shares held by the Company.
How many total shares does Oculis Holding AG have?
Oculis has a total of 48,943,700 registered shares, with approximately 43 million shares currently outstanding.
What is the purpose of the New Shares issued by Oculis?
The New Shares were issued as treasury shares related to an at-the-market offering program with Leerink Partners.
What is the ATM offering program mentioned in the release?
The ATM offering program allows Oculis to offer up to $100 million in ordinary shares at its discretion through Leerink Partners.
Where can I find more information about Oculis?
More information about Oculis can be found on their official website at http://www.oculis.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCS Hedge Fund Activity
We have seen 4 institutional investors add shares of $OCS stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABRDN PLC added 188,871 shares (+23.0%) to their portfolio in Q4 2024, for an estimated $3,210,807
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 50,366 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $617,487
- NORTHERN TRUST CORP added 13,565 shares (+inf%) to their portfolio in Q3 2024, for an estimated $166,306
- UBS GROUP AG added 1,277 shares (+7.7%) to their portfolio in Q3 2024, for an estimated $15,656
- BANK OF AMERICA CORP /DE/ added 1,158 shares (+6.8%) to their portfolio in Q3 2024, for an estimated $14,197
- ROYAL BANK OF CANADA removed 4 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $49
- COMPAGNIE LOMBARD ODIER SCMA added 0 shares (+0.0%) to their portfolio in Q4 2024, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 48,943,700, of which approximately 43 million shares are outstanding. Following the issuance, the number of treasury shares (own shares) held by the Company is 7.2% of the Company’s registered shares.
The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”) entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The New Shares have not been sold under the ATM offering program and will be held in reserve as treasury shares.
For more details on the ATM offering program, please refer to the Company’s previous press release dated May 17, 2024, and the Company’s SEC filings referenced therein.
For more information, please visit:
http://www.oculis.com
Oculis Contact:
Ms. Sylvia Cheung, CFO
[email protected]
Investor & Media Relations:
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
1-212-915-2577
